Testing a new antibiotic for severe urinary infections in the blood
Part of Infections clinical trials.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed complicated urinary tract infection that has spread to your bloodstream
- The infection must be caused by a type of bacteria that the trial drugs can kill
- You cannot be allergic to cefepime or related drugs
- You must be well enough to give your consent and not be in palliative care
- You cannot have received the wrong antibiotics for more than 48 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This study tests a new antibiotic for children with difficult-to-treat urinary tract infections (UTIs). The medicine is given through an IV and may help when other antibiotics haven't worked.
This trial tests whether the antibiotic cefotetan works as well as or better than standard treatments for E. coli bloodstream infections. You may be eligible if you have a confirmed E. coli infection in your blood that started in your urinary or genital area, and you have just started antibiotics in the hospital.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Antibiotic Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.